Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Chimeric antigen receptor T (CAR-T) cell therapy has significantly transformed the management of cancer, specifically in patients suffering from leukemia and lymphoma. This treatment approach entails ...
Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...
Tumor immunotherapies, especially those leveraging T cells to identify and eliminate cancer cells, represent a major breakthrough in cancer treatment. However, many tumor-associated antigens are too ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners (MOLN) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results